Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) Revenue
Annual & quarterly revenue history · segment & region breakdown
RARE · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsUltragenyx Pharmaceutical Inc. trailing twelve-month (TTM) revenue is $0.67B, an increase of 20.13% year-over-year from $0.67B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.67B | +$0.11B | +20.13% |
| 2024-12-31 | $0.56B | +$0.13B | +29.01% |
| 2023-12-31 | $0.43B | +$0.07B | +19.52% |
| 2022-12-31 | $0.36B | +$0.01B | +3.39% |
| 2021-12-31 | $0.35B | +$0.08B | +29.66% |
| 2020-12-31 | $0.27B | +$0.17B | +161.32% |
| 2019-12-31 | $0.10B | +$0.05B | +101.41% |
| 2018-12-31 | $0.05B | +$0.05B | +1871.48% |
| 2017-12-31 | $0.00B | +$0.00B | +1863.91% |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare RARE revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ultragenyx Pharmaceutical Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ultragenyx Pharmaceutical Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Ultragenyx Pharmaceutical Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
RARE revenue · 4 questionsRARE's trailing twelve-month (TTM) revenue is $0.67B. That is an increase of 20.13% year-over-year from $0.67B in FY2025.
▸ Source: FMP · Ultragenyx Pharmaceutical Inc. SEC filings · GAAP · Ultragenyx Pharmaceutical Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026